Patent Law Updates For Neural-AI-Driven Biotechnology And Personalized Medicine

01 Apr 2026 --
0 Comments

1. Overview: Neural AI and Personalized Medicine in Patents

Neural-AI-driven biotechnology combines artificial intelligence, machine learning, and computational models with biological research. Personalized medicine leverages patient-specific data (genomics, proteomics, clinical history) to tailor therapies.

Patent law in these areas revolves around two main challenges:

Patent-eligible subject matter – Can AI-generated inventions or algorithms applied to biological processes be patented?
Inventorship and novelty – Who is the inventor: the AI system, the human user, or both? Are AI-optimized treatments considered novel or obvious?

Most patent offices, including the USPTO and EPO, rely on traditional frameworks but adapt them with emerging guidance for AI-generated inventions and biotechnological processes.

2. Key Legal Principles

A. Subject Matter Eligibility (US law – 35 U.S.C. §101)

Natural phenomena, abstract ideas, and laws of nature are not patentable.
In biotechnology and AI, this affects algorithms predicting protein structures, genomic patterns, or personalized drug regimens.

B. Inventorship

Only humans can be inventors under current US law.
AI tools assisting in discovery do not qualify as inventors (see Thaler v. USPTO, discussed below).

C. Obviousness and Novelty

AI can analyze massive datasets; however, merely using AI to automate routine tasks doesn’t make an invention non-obvious.
Novel AI-designed molecules or gene therapies can qualify if they meet inventive step criteria.

3. Detailed Case Laws

Case 1: Alice Corp. v. CLS Bank International (2014, US Supreme Court)

Relevance: Sets limits on patenting abstract ideas, including AI algorithms.

Facts: Alice patented a computerized method for mitigating settlement risk in financial transactions. CLS Bank argued it was an abstract idea implemented on a computer.
Decision: Patents claiming abstract ideas implemented on generic computers are not patentable.
Impact on AI biotech: Neural networks or algorithms for predicting drug response may be considered abstract ideas unless tied to a specific, novel method or practical application (e.g., a specific therapeutic method or diagnostic tool).

Case 2: Mayo Collaborative Services v. Prometheus Laboratories, Inc. (2012, US Supreme Court)

Relevance: Limits patents on natural correlations in personalized medicine.

Facts: Prometheus patented a method for adjusting drug dosage based on metabolite levels in patients. Mayo argued it was a natural law.
Decision: The Supreme Court held that correlations between natural biomarkers and dosage are not patentable unless there’s a novel application beyond the natural law.
Impact: AI-driven diagnostics must show specific interventions or treatment steps, not just predictive correlations.

Case 3: AMP v. Myriad Genetics (2013, US Supreme Court)

Relevance: Patent eligibility of naturally occurring genes.

Facts: Myriad patented isolated BRCA1 and BRCA2 genes linked to breast cancer.
Decision: Naturally occurring DNA sequences cannot be patented, but complementary DNA (cDNA), synthesized in a lab, can be patentable.
Impact: AI-generated synthetic gene sequences or designed proteins may qualify, but natural sequences alone do not.

Case 4: Thaler v. USPTO (DABUS AI Invention Cases, 2021–2023)

Relevance: Inventorship in AI-driven inventions.

Facts: Dr. Stephen Thaler applied for patents listing DABUS AI as the inventor, for AI-designed products and compounds.
Decision: USPTO, EPO, and UKIPO rejected AI inventors, ruling only humans can be inventors.
Impact: In neural-AI-driven biotech, the human guiding AI must be listed as the inventor, even if AI contributed substantially.

Case 5: In re Roslin Institute (Dolly the Sheep, 2003, US Federal Circuit)

Relevance: Patent eligibility of cloned animals.

Facts: The Roslin Institute tried to patent cloned sheep (Dolly).
Decision: Cloned animals derived from natural processes are not patentable unless the process or genetic modification is inventive.
Impact: AI-designed genetically modified organisms may qualify if there’s an inventive step beyond natural replication.

Case 6: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals (2018, US Federal Circuit)

Relevance: Personalized medicine patenting.

Facts: Vanda patented a method for dosing iloperidone based on patient genotype (CYP2D6).
Decision: Court upheld patent, ruling the treatment method was patentable because it involved a specific application of a natural correlation.
Impact: AI algorithms predicting drug dosage may be patentable if tied to specific treatment regimens, even if using naturally occurring biomarkers.

Case 7: Sequenom, Inc. v. Ariosa Diagnostics (2015, US Federal Circuit)

Relevance: Diagnostic method patent eligibility.

Facts: Sequenom patented non-invasive prenatal testing (NIPT) using fetal DNA in maternal blood.
Decision: Court invalidated the patent as the method relied on naturally occurring DNA and routine techniques.
Impact: Personalized AI-based diagnostics must add more than routine steps; must show inventive methodology.

4. Key Trends and Updates

AI algorithms are patentable only when applied to a practical, technical solution – e.g., AI-designed protein with a specific function, not just prediction.
Personalized medicine patents require a concrete application – correlating biomarkers alone is insufficient.
Inventorship remains human-centric, but AI is increasingly recognized as a tool in inventive processes.
Synthetic biology and AI-designed molecules are emerging patentable areas, especially when creating sequences or structures not found in nature.
Global divergence: EPO allows more flexibility for AI-assisted inventions, while US law is stricter on natural correlations.

✅ Summary Table of Cases

Case	Year	Key Issue	Outcome	Impact on Neural-AI/Personalized Medicine
Alice v. CLS Bank	2014	Abstract ideas	Not patentable	AI algorithms need specific applications
Mayo v. Prometheus	2012	Natural correlations	Not patentable	Biomarker-based dosing needs practical steps
AMP v. Myriad	2013	Gene sequences	cDNA patentable	AI-designed synthetic genes qualify
Thaler v. USPTO	2021	AI inventorship	Only humans	Human inventors required for AI output
Roslin Institute	2003	Cloned animals	Natural cloning not patentable	AI-designed GMOs can be patentable
Vanda Pharmaceuticals	2018	Personalized dosing	Patent upheld	AI dosage methods may qualify
Sequenom v. Ariosa	2015	Diagnostics	Invalid	Routine diagnostic steps insufficient